OncoZenge AB (publ) (FRA:8LY)

Market Cap	7.22M +12.3%
Revenue (ttm)	257.25K +278,300.0%
Net Income	-1.47M
EPS	-0.12
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.5270
Previous Close	0.5270
Day's Range	0.5270 - 0.5270
52-Week Range	0.3400 - 0.6680
Beta	n/a
RSI	51.70
Earnings Date	Apr 30, 2026

About OncoZenge AB

OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2020
• Employees: 1
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8LY

Financial Performance

In 2025, OncoZenge AB's revenue was 2.78 million, an increase of 278300.00% compared to the previous year's 1,000. Losses were -15.94 million, 83.5% more than in 2024.

Financial numbers in SEK